Frequent downregulation or loss of CD79a expression in plasma cell myelomas: Potential clue for diagnosis

Pathology International

Volumn 59, Issue 11, 2009, Pages 804-808

  Tanaka, Takehiro ^a   Ichimura, Kouichi ^a   Sato, Yasuharu ^a   Takata, Katsuyoshi ^a   Morito, Toshiaki ^a   Tamura, Maiko ^a   Kondo, Eisaku ^a   Ohara, Nobuya ^a   Yanai, Hiroyuki ^a   Sakai, Masaharu ^b   Takahashi, Satoru ^c   Yoshino, Tadashi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

C maf; CD79a; Cyclin D1; Myeloma

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CALCIUM; CD20 ANTIGEN; CD79A ANTIGEN; CREATININE; CYCLIN D1; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; SYNDECAN 1; TRANSCRIPTION FACTOR C MAF;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STAINING; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD20; ANTIGENS, CD79; CYCLIN D1; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-MAF;

EID: 70350503050     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2009.02448.x     Document Type: Article

References (22)

1. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon : IARC Press, 2008.
2. Mason DY, Cordell JL, Brown MH et al. Cd79a: A novel marker for b-cell neoplasms in routinely processed tissue samples. Blood 1995 86 : 1453 1459.
3. Mason DY, Cordell JL, Tse AG et al. The IgM-associated protein mb-1 as a marker of normal and neoplastic B-cells. J Immunol 1991 147 : 2474 2482.
4. Cassard S, Choquet D, Fridman WH, Bonnerot C. Regulation of ITAM signaling by specific sequences in Ig-beta B cell antigen receptor subunit. J Biol Chem 1996 271 : 23 786 91.
5. Tseng J, Eisfelder BJ, Clark MR. B-cell antigen receptor-induced apoptosis requires both Ig alpha and Ig beta. Blood 1997 89 : 1513 1520.
6. Pike KA, Iacampo S, Friedmann JE, Ritcliffe MJ. The cytoplasmic domain of Ig alpha is necessary and sufficient to support efficient early B-cell development. J Immunol 2004 172 : 2210 2218.
7. Vilen BJ, Burke KM, Sleater M, Cambier JC. Transmodulation of BCR signaling by transduction-incompetent antigen receptors: Implications for impaired signaling in anergic B-cells. J Immunol 2002 168 : 4344 4351.
8. Mielenz D, Ruschel A, Vettermann C, Jack HM. Immunoglobulin mu heavy chains do not mediate tyrosine phosphorylation of Ig alpha from the ER-cis-Golgi. J Immunol 2003 171 : 3091 3101.
9. Ott MM, Helbing A, Ott G et al. bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma. J Pathol 1996 179 : 238 242.
10. Yatabe Y, Nakamura S, Seto M et al. Clinicopathologic study of PRAD1/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma. A distinct molecular pathologic entity. Am J Surg Pathol 1996 20 : 1110 1122.
11. Zukerberg LR, Yang WI, Arnold A, Harris NL. Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry. Am J Clin Pathol 1995 103 : 756 760.
12. Vasef MA, Medeiros LJ, Yospur LS, Sun NC, McCountry A, Brynes RK. Cyclin D1 protein in multiple myeloma and plasmacytoma: An immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol 1997 10 : 927 932.
13. Chesi M, Bergsagel PL, Shnukan OO et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998 91 : 4457 4463.
14. Hurt EM, Wiestner A, Rosenwald A et al. Over expression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004 5 : 191 199.
15. Kuehl WM, Bergsagel PL. Multiple myeloma: Evolving genetic events and interactions. Nat Rev Cancer 2002 2 : 175 187.
16. Saidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003 4 : 557 564.
17. Kienast J, Berdel WE. c-maf in multiple myeloma: An oncogene enhancing tumor-stroma interactions. Cancer Cell 2004 5 : 109 110.
18. Zhan F, Huang Y, Colla S et al. The molecular classification of multiple myeloma. Blood 2006 108 : 2020 2028.
19. Cavo M, Galieni P, Zuffa E, Gobbi M, Tura S. Prognostic variables and clinical staging in multiple myeloma. Blood 1989 74 : 1774 1780.
20. Lai R, Medeiros LJ, Wilson CS et al. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: Correlation with cyclin-D1 immunoreactivity. Mod Pathol 1998 11 : 642 647.
21. Akthanasiou E, Kaloutsi V, Kotoula V et al. Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens. Am J Clin Pathol 2001 116 : 535 542.
22. Markovic O, Marisavljevic D, Cemerikic V, Suvajdzic N, Millic N, Colovic M. Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: Relationship to proliferative activity and prognostic significance. Med Oncol 2004 21 : 73 80.